The goal of this clinical trial is to learn if targeted medical therapy will improve symptoms and quality of life in patients with angina and non-obstructive coronary arteries compared to placebo, after the underlying cause of the chest pain has been ascertained by coronary function testing.
Participants will be treated with either medications that target the underlying cause of their chest pain or placebo for 50 days. They will be asked to complete a series of questionnaires to evaluate their quality of life at the beginning and end of the study.

开始日期2024-07-01

申办/合作机构

Stanford University

[+1]

NCT06236061 / Recruiting临床3期

A Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696/Amlodipine 200/2.5 mg, 200/5 mg and 200/10 mg Compared to LCZ696 200 mg Alone in Patients With Grade 1 and 2 Hypertension Not Adequately Controlled by LCZ696 200 mg Monotherapy

This CLAZ696B11302 study is composed of two parts; the Core part including double-blind period, and the open-label extension (OLE) part which is an open-label extension of the Core part.
The purpose of the Core part is to demonstrate that LCZ696 (LCZ) when used in combination with amlodipine (AML), denoted as LCZ/AML, will provide greater blood pressure lowering benefit compared to LCZ monotherapy in patients with grade 1 and 2 hypertension not adequately controlled with LCZ monotherapy. The purpose of the OLE part is to assess the long-term safety, tolerability and efficacy of the treatment with LCZ/AML.

开始日期2024-04-08

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT05917275 / Recruiting临床4期

Multi-Omics to Predict the Blood Pressure Response to Antihypertensives

The goal of this clinical trial is to develop biomarkers composed of multiple OMICs (MOMICs) for prediction of blood pressure response to antihypertensive drugs in the treatment of primary hypertension. The main objectives are:
Primary objective:
- To identify MOMICs biomarkers that predict the response in 24-hour blood pressure to antihypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine)
Secondary objectives:
To identify a MOMICs biomarker that predict the response in night-time blood pressure to anti-hypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine)
To identify MOMICs biomarkers that predict side effects, including changes in QoLof olmesartan, amlodipine and hydrochlorothiazide.
Exploratory objective:
To assess changes in MOMICs biomarkers induced by each drug
Participants will undergo three 4-week treatment periods:
Each subject receives 3 out of 4 possible treatments (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine).
Before and after each treatment period OMICS measurements and an ABPM are performed.
At the end of each treatment period blood is sampled for drug level testing to assess adherence.
Electrolytes and kidney function are checked 5-7 days after start of each treatment period.

开始日期2024-04-04

申办/合作机构

Radboud University Medical Center

100 项与氨氯地平相关的临床结果

登录后查看更多信息

100 项与氨氯地平相关的转化医学

登录后查看更多信息

100 项与氨氯地平相关的专利（医药）

登录后查看更多信息

5,613

项与氨氯地平相关的文献（医药）

2024-05-01·Current drug safety

Tizanidine Induced Hypotension: Report of a Case and Review of the Literature

Review

作者: Kalita, Jayantee ; Mahajan, Roopali

Introduction::

Spasticity is a common sequelae of stroke, and often these patients receive anti-spastic drugs such as baclofen or tizanidine. Stroke patients have multiple co-morbidities such as hypertension, diabetes, and seizure. Tizanidine is an α2 and imidazole receptor agonist at a spinal and supraspinal level resulting in reduced central sympathetic outflow and causing hypotension rarely, especially in those receiving beta-blockers or angiotensin-converting enzyme inhibitors.

Case Presentation::

We report a 56-year-old hypertensive male presenting with altered sensorium who had recurrent intracerebral hemorrhage with left spastic hemiplegia and focal seizures. He was on amlodipine, atenolol, telmisartan and oxcarbazepine. After 3 doses of tizanidine 2mg, his blood pressure dropped from 140/90 to 80/40 mmHg and pulse from 82 bpm to 44 bpm. His blood counts, serum chemistry, procalcitonin, and Trop I were normal. ECG revealed sinus bradycardia. After 8 hours of withdrawing tizanidine, his blood pressure became 110/70 mmHg, and on the next day, it became 140/82 mmHg. His attendants were taught physiotherapy to minimize spasticity.

Conclusion::

This patient highlights the need for close monitoring of patients receiving tizanidine co-medication with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. These drugs have a synergistic effect on reducing the renin-angiotensin-aldosterone system, thereby hypotension and bradycardia.

2024-03-01·Journal of the American Geriatrics Society

Fall risk and cardiovascular outcomes of first‐line antihypertensive medications in nursing home residents

Article

作者: Zhang, Yuan ; Lee, Yoojin ; Zhang, Tingting ; Hayes, Kaleen ; Ko, Darae ; Zullo, Andrew R ; Berry, Sarah D ; Kim, Dae H ; Daielo, Lori ; Kiel, Douglas P

Abstract:

Background:

Little evidence exists about the comparative effects of first‐line antihypertensive medications (i.e., renin‐angiotensin‐aldosterone converting enzyme inhibitors (RAASi), amlodipine, or thiazide diuretics) in older adults with limited life expectancy. We compared the rates of injurious falls and short‐term cardiovascular events between different first‐line antihypertensive medication classes in adults receiving care in nursing homes (NH).

Methods:

This was a retrospective cohort of Medicare fee‐for‐service beneficiaries receiving care in NHs. Patients newly dispensed first‐line antihypertensive medications were identified using Part D claims (2015–2018) and linked with clinical assessments (i.e., Minimum Data Set). Fall‐related injuries (FRI), hip fractures, and major adverse cardiac events (MACE) outcomes were identified using hospitalization claims. Patients were followed from the date of antihypertensive dispensing until the occurrence of outcomes, death, disenrollment, or 6‐month follow‐up. Inverse‐probability‐of‐treatment‐weighted (IPTW) cause‐specific hazards regression models were used to compare outcomes between patients who were new users of RAASi, amlodipine, or thiazides.

Results:

Our cohort included 16,504 antihypertensive users (RAASi, n = 9574; amlodipine, n = 5049; thiazide, n = 1881). Mean age was 83.5 years (± 8.2), 70.6% were female, and 17.2% were non‐white race. During a mean follow‐up of 5.3 months, 326 patients (2.0%) experienced an injurious fall, 1590 (9.6%) experienced MACE, and 2123 patients (12.9%) died. The intention‐to‐treat IPTW hazard ratio (HR) for injurious falls for amlodipine (vs RAASi) use was 0.85 (95% confidence interval (CI) 0.66–1.08) and for thiazides (vs RAASi) was 1.22 (95% CI 0.88–1.66). The rates of MACE were similar between those taking anti‐hypertensive medications. Thiazides were discontinued more often than other classes; however, inferences were largely unchanged in as‐treated analyses. Subgroup analyses were generally consistent.

Conclusions:

Older adults with limited life expectancy experience similar rates of injurious falls and short‐term cardiovascular events after initiating any of the first‐line antihypertensive medications.

2024-03-01·Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Utility of Cilefa Pink B, a foodstuff dye as a fluoro-substrate in the devising of the first facile green Molecular-mass-Related Fluorescence Sensor for quantifying amlodipine in batched material and dosage forms; content uniformity evaluation

Article

作者: Mahdi, Wael A ; Alshehri, Sultan ; Abdulhafez Hamad, Ahmed ; Abdelrahman, Kamal S ; Abdel-Aal, Mohamed A A ; Soltan, Osama M ; Fouad, Ali ; Saad Al-Farhan, Badriah ; Soltan, Moustafa K ; El Hamd, Mohamed A

This study introduces the first and unique Molecular-mass-Related Fluorescence Sensor as the first fluorimetric strategy for determining amlodipine. An environmentally friendly, single-step, and direct spectrofluorimetric approach was utilized to evaluate the analyte. In an acidic setting, combining the amlodipine medication and the fluorescent dye Cilefa Pink B generated an instantaneous ultra-fluorescent product. An increase in dye response after adding amlodipine was proportional to the molecular weight of the generated complex, as measured at 329 nm. was the idea ofthe applied fluorimetric analysis. The complexing process increased the molecular mass from 879.86 to 1288.739 g mol^-1. The medication's range of 0.050-1.00 µg mL^-1 is directly correlated with this molecular massenlargement. The ideal settings for the changeable parameters of the system were established through an analysis of the response of the amlodipine-Cilefa Pink B system. Furthermore, the developed sensor complied with ICH (International Council for Harmonization) standards. The sensitivity limits were 0.0139 µg mL^-1 (for the detection limit, LOD) and 0.042 µg mL^-1 (for the quantification limit, LOQ). Additionally, this method effectively recovered the drug in its original and therapeutic dosage forms. Finally, the proposed process's environmental impact was also assessed through different modern greenness evaluation tools.

257

项与氨氯地平相关的新闻（医药）

2024-06-06

·drugs

Several Drugs Linked to Risk for Aneurysmal Subarachnoid Hemorrhage

THURSDAY, June 6, 2024 -- Several commonly prescribed drugs are associated with aneurysmal subarachnoid hemorrhage (aSAH), according to a study published online June 5 in Neurology . Jos P. Kanning, from the University Medical Center Utrecht in the Netherlands, and colleagues conducted a drug-wide association study to examine the association between commonly prescribed drugs and aSAH incidence. Use of commonly prescribed drugs was examined across exposure windows (current, within three months; recent, three to 12 months; and past, >12 months). Exposure to 205 commonly prescribed drugs was investigated among 4,879 aSAH cases and 43,911 matched controls. The researchers found similar trends for lisinopril and amlodipine, with a decreased risk for aSAH in association with current use, while the risk for aSAH was increased with recent use. The risk for aSAH was reduced with current use of simvastatin, metformin, and tamsulosin. Increased aSAH risk was seen in association with current use of warfarin, venlafaxine, prochlorperazine, and co-codamol. "Future research should use a more hypothesis-driven approach to further investigate these associations and differentiate between drug class and specific drug substance effects," the authors write. "In addition, this research may help identify additional risk factors for aSAH, potentially leading to new pharmacologic therapy options for aneurysmal management." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果临床研究

2024-06-04

·BioSpace

GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Company exploring path forward for uproleselan in multiple AML settings based on observed efficacy results, including clinically meaningful results in primary refractory AML, and significant unmet patient need Uproleselan demonstrated a clinically meaningful improvement in median overall survival (mOS) for patients with primary refractory AML; mOS was 31.2 months for the uproleselan arm compared to 10.1 months for the placebo arm in this subgroup Adverse events for uproleselan were consistent with known side effect profiles of chemotherapy used in the study Advancing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology for Phase 2/3 study of uproleselan with chemotherapy in older adults with frontline AML Conference call and webcast to be hosted today, June 4, 2024, at 8:30 am E.T. ROCKVILLE, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced comprehensive results from the company’s pivotal Phase 3 study of uproleselan in R/R AML. “There is a wealth of data across large subsets of this pivotal Phase 3 study that help us understand how prespecified stratification factors such as backbone chemotherapy, disease status, and age impacted survival outcomes for patients,” said Daniel DeAngelo, M.D., Ph.D., Professor of Medicine, Harvard Medical School, Chief, Division of Leukemia, Dana-Farber Cancer Institute, and Principal Investigator of the pivotal Phase 3 study. “In the primary refractory setting, uproleselan’s improvement of mOS and greater duration of remission were particularly compelling, as there is a significant unmet need for new treatment options in this setting that can extend and improve the lives of patients. These results demonstrate uproleselan has the potential to address this unmet need in primary refractory AML.” “As we have analyzed data from this large, well-balanced, and well-executed study alongside medical, statistical, and regulatory experts, it has become clear that uproleselan may offer clinically meaningful patient benefit in multiple settings, including primary refractory AML,” said Harout Semerjian, Chief Executive Officer of GlycoMimetics. “We are committed to addressing unmet needs of AML patients and plan to engage with regulators and NCI to discuss potential paths forward for uproleselan.” Results of Pivotal Phase 3 Study of Uproleselan in R/R AML The randomized, double-blind, placebo-controlled Phase 3 clinical study evaluated uproleselan in combination with MEC (mitoxantrone, etoposide and cytarabine) or FAI (fludarabine, cytarabine and idarubicin) in patients with R/R AML. Patients received either uproleselan or placebo for 8 days over 1 cycle of induction and, if applicable, up to 3 cycles of consolidation. The primary endpoint was overall survival (OS), which was not censored for transplant. Secondary endpoints included incidence of severe oral mucositis, complete remission (CR) rate and CR with partial hematologic recovery (CRh). A total of 388 patients in nine countries were randomized 1:1 between treatment and placebo arms. There were 59 sites that enrolled at least one patient. Median follow up was over three years at the time of primary analysis. Overall Survival Primary Endpoint: mOS in the intent-to-treat (ITT) population (n=388) was 13.0 months for the uproleselan arm, compared to 12.3 months for the placebo arm (hazard ratio [HR] 0.89; 95% confidence interval [CI] 0.69-1.15); this difference is not statistically significant. Disease Status Primary Refractory: mOS for primary refractory patients in the uproleselan arm (n=62) was 31.2 months, compared to 10.1 months (HR 0.58; 95% CI 0.37-0.91) for the placebo arm (n=66). This benefit was irrespective of backbone chemotherapy. Median duration of response (DoR) for complete remission (CR) was not reached for primary refractory patients in the uproleselan arm compared to a median DoR of 12.7 months for the placebo arm. Early Relapse: mOS for early relapse patients in the uproleselan arm (n=28) was 3.7 months, compared to 6.4 months (HR 1.50; 95% CI 0.69-3.27) for the placebo arm (n=22). Late Relapse: mOS for late relapse patients in the uproleselan arm (n=104) was 15.4 months, compared to 18.2 months (HR 1.10; 95% CI 0.77-1.57) for the placebo arm (n=106). Backbone Chemotherapy: FAI: mOS for patients treated with uproleselan plus FAI (n=98) was 30.2 months compared to 12.8 months (HR 0.73; 95% CI 0.50-1.06) for patients treated with FAI alone (n=96) in the ITT population. MEC: mOS for patients treated with uproleselan plus MEC (n=96) was 8.7 months compared to 12.3 months (HR 1.06; 95% CI 0.75-1.51) for patients treated with MEC alone (n=98) in the ITT population. Transplantation Status: For patients who received hematopoietic stem cell transplantation (HSCT) after study treatment, mOS was not reached for patients in the uproleselan arm (n=101). In contrast, for HSCT patients in the placebo arm, mOS for patients receiving FAI (n=53) was 26.3 months and for patients receiving MEC (n=46) was 24.4 months. Secondary Endpoints 7.2% of patients in each arm (n=388) experienced induction emergent severe oral mucositis. 36.1% of patients in the uproleselan arm (n=194) experienced CR at the end of induction (EOI) as determined by an independent endpoint review committee (IERC), compared to 33.5% of patients in the placebo arm (n=194). 46.4% of patients in the uproleselan arm experienced CR/CRh at EOI as determined by IERC, compared to 41.2% of patients in the placebo arm. Post-treatment HSCT rate was 52.1% in the uproleselan arm and 51.0% in the placebo arm. Subsequent AML therapy in non-responders was 40.0% in the uproleselan arm (n=80) and 46.2% in the placebo arm (n=78). Safety Adverse events were consistent with the known safety pro backbone chemotherapy regimens. 35.9% of patients in the uproleselan arm experienced serious treatment-emergent adverse events (TEAEs) compared to 34.2% in the placebo arm. 85.9% of patients in the uproleselan arm experienced grade 3 or higher TEAEs compared to 87.6% in the placebo arm. NCI Phase 2/3 Study of Uproleselan in Frontline AML In addition to the company’s pivotal Phase 3 trial of uproleselan, the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology are conducting an adaptive Phase 2/3 study of uproleselan in adults with newly diagnosed AML who are 60 years or older and fit for intensive chemotherapy. Their randomized, controlled study is evaluating the addition of uproleselan to a standard cytarabine / daunorubicin regimen (7+3) versus chemotherapy alone. The Phase 2 portion of the study completed enrollment of 267 patients in December 2021. The Company is advancing discussions with the NCI and the Alliance for Clinical Trials in Oncology based on the results of the pivotal Phase 3 study of uproleselan in R/R AML. Conference Call Details To access the call by phone, please go to this registration link and you will be provided with dial in details. Participants are encouraged to connect 15 minutes in advance of the scheduled start time. A live webcast of the call and the corresponding slides will be available on the “Investors” tab on the GlycoMimetics website. A webcast replay will be available for 30 days following the call. About AML AML is the most common acute leukemia in adults. A cancer of the bone marrow, nearly 21,000 people in the United States are diagnosed with AML each year. Despite the availability of multiple treatments, disease prognosis is poor, and new treatment options are needed to improve outcomes. Newly diagnosed AML has the lowest 5-year survival rate of all leukemias at 31.7%. The five-year survival rate for people with relapsed/refractory disease is only 10%. About Uproleselan Discovered and developed by GlycoMimetics, uproleselan (yoo’ pro le’se lan) is an investigational, first-in-class E-selectin antagonist. GlycoMimetics has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA) and Breakthrough Therapy designation from the Chinese National Medical Products Administration for uproleselan as a potential treatment for adult AML patients with relapsed or refractory disease. E-selectin is a leukocyte adhesion molecule constitutively expressed on endothelial cells of the vasculature and bone marrow. In AML, there is evidence that E-selectin–ligand interaction between endothelial cells in the protective niche of the Bone Marrow microEnvironment (BME) and leukemic stem cells and blasts promotes leukemic cell survival and hides them from AML therapies. Uproleselan is designed to disrupt E-selectin binding and prevent leukemic myeloid cells using the protective niche of the BME. About GlycoMimetics, Inc. GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases. The company’s scientific approach is based on an understanding of the role that carbohydrates play in cell recognition. Its specialized chemistry platform is being deployed to discover small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. GlycoMimetics is leveraging its differentiated expertise with this scientific approach in order to advance its pipeline of wholly owned drug candidates. The company’s goal is to develop transformative therapies for diseases with high unmet medical need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at . Forward-Looking Statements This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of, and timing for analysis and presentation of data from, clinical trials; potential development and regulatory activities; and the potential benefits and impact of uproleselan. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2024, the company’s Quarterly Report on Form 10-Q filed with the SEC on May 9, 2024, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.

临床结果临床3期临床2期快速通道突破性疗法

2024-06-03

·Pharma CMC

今日109个新批件！超50个品种获批！齐鲁、扬子江、石四药……

限时免费报名中刚刚，NMPA发布2024年06月03日药品批准证明文件送达信息，本批次共有109个受理号获批，其中4个为一致性评价受理号，过评品种为：北京四环科宝制药股份有限公司，米格列奈钙片上海现代制药股份有限公司，3品规替米沙坦片本次共有70个上市申请受理号获批，涉及50多个品种，其中：厦门恩成制药的2.2类新药兰索拉唑碳酸氢钠胶囊获批上市。此前，兰索拉唑碳酸氢钠胶囊为上海信谊万象药业的独家品种。兰索拉唑碳酸氢钠胶囊是质子泵抑制剂复方制剂，这类复方制剂的优势在于，抗酸药（碳酸氢钠）可直接中和胃酸，使兰索拉唑在吸收前不被胃酸分解，从而达到持久抑制胃酸的效果。齐鲁制药的泊马度胺胶囊获批上市，为国内第二家获批。2020年11月，正大天晴的泊马度胺胶囊获批上市，拿下国内“首仿”。泊马度胺为第三代免疫调节剂，适用于既往已接受至少两种治疗包括来那度胺和硼替佐米，且被证实疾病进展或末次治疗完成60天内的多发性骨髓瘤患者。原研药由新基公司开发，于2013年2月获FDA批准上市，同年8月在欧洲获批，尚未进入中国。石家庄四药的比索洛尔氨氯地平片获批上市，视同通过一致性评价，为国内企业第二家获批。比绍洛尔氨氯地平片是复方制剂，主要用于作为高血压治疗的替代疗法。除上述品种外还有，扬子江药业集团广州海瑞药业的阿加曲班注射液；江苏联环药业的醋酸阿比特龙片；四川美大康华康药业的帕拉米韦注射液；石药集团欧意药业的奥拉帕利片；广东金城金素制药的注射用阿莫西林钠等大批品种获批。欢迎添加微信，进入批件之家仅供交流，与官方无关

上市批准一致性评价

100 项与氨氯地平相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07450	-	-	DB00381

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
心绞痛	日本	VIATRIS Pharmaceuticals Ltd.	1993-10-01
高血压	日本	VIATRIS Pharmaceuticals Ltd.	1993-10-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
冠心病	申请上市	中国	一品红药业股份有限公司	2022-06-03
左心室肥大	临床3期	德国	Novartis AG	2007-03-01
原发性高血压	临床3期	美国	Novartis AG	2006-11-01
原发性高血压	临床3期	比利时	Novartis AG	2006-11-01
原发性高血压	临床3期	丹麦	Novartis AG	2006-11-01
原发性高血压	临床3期	芬兰	Novartis AG	2006-11-01
原发性高血压	临床3期	德国	Novartis AG	2006-11-01
原发性高血压	临床3期	冰岛	Novartis AG	2006-11-01
原发性高血压	临床3期	印度	Novartis AG	2006-11-01
原发性高血压	临床3期	瑞士	Novartis AG	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03860220 (Pubmed)	临床4期	血脂障碍 \| 高血压	304	Telmisartan 40 mg/Amlodipine 5 mg/Rosuvastatin 10 mg	艱簾壓艱積範遞獵鹽網(築觸蓋簾觸願鏇觸製築) = 憲壓願鬱餘獵繭積餘網網糧顧鹽鬱築選顧壓範 (繭憲憲簾製鑰醖夢範襯, 1.18)	-	2024-01-01
				Amlodipine 5 mg/Atorvastatin 10 mg	艱簾壓艱積範遞獵鹽網(築觸蓋簾觸願鏇觸製築) = 築築積積鏇鬱衊選願選網糧顧鹽鬱築選顧壓範 (繭憲憲簾製鑰醖夢範襯, 1.17)
ESC2023	临床3期	原发性高血压	532	Perindopril arginine 5 mg/Indapamide 1.25 mg/Amlodipine 5 mg (P5/I1.25/A5)	網壓鏇繭壓繭鏇選艱繭(鬱鹹選觸鏇選淵鏇鹽構) = 餘獵壓製襯網網淵觸鬱夢襯獵鏇構壓鏇膚繭網 (蓋構製廠鏇獵憲遞膚積 ) 更多	积极	2023-08-27
				Perindopril tert-butylamine 4 mg/Indapamide 1.25 mg (P4/I1.25) plus Amlodipine 5 mg (P4/I1.25 +A5)	壓範鹹憲餘廠鹽餘構簾(獵廠鏇獵範衊選壓餘淵) = 廠衊構衊鬱廠簾齋顧選壓簾積遞襯醖壓築鑰築 (鏇夢膚窪觸築壓願襯艱 ) 更多
ESC2023	N/A	高血压	30	Amlodipine/valsartan	淵壓觸艱築獵顧選醖壓(網蓋築鬱艱選範餘構餘) = 鑰鹽憲簾憲餘網鑰鑰遞選範壓壓鹹窪蓋齋鏇顧 (鏇廠淵膚願簾齋遞構選 ) 更多	积极	2023-08-25
Pubmed	N/A	高同种半胱胺酸血症 \| 高血压	351	Amlodipine-FA tablet (amlodipine 5 mg/FA 0.4 mg)	-	积极	2023-07-11
				Amlodipine 5 mg/FA 0.8 mg tablet
WCD2023	N/A	牙龈肥大	-	Amlodipine/Valsartan combination	繭鏇夢艱夢遞顧醖醖觸(壓簾膚鬱積窪鬱蓋衊願) = On examination, we observe a firm anterior GH affecting the papillae, a mobile and attached gingiva with partial covering of the teeth and respect of the edentulous areas associated with tartaric gingivitis 齋膚淵壓繭夢簾觸鹽簾 (廠網憲衊遞淵窪餘構積 )	-	2023-07-03
NCT03461003 (CTgov)	临床4期	高血压	49	Lisinopril+Hydrochlorothiazide+Amlodipine+Losartan (NICHE Method)	遞鑰餘願餘襯鬱鬱鹽衊(鹽繭糧顧製觸憲鹽壓淵) = 簾製簾鹽衊襯壓構窪餘築齋製夢鹹壓遞窪鹽壓 (繭憲製膚夢獵鹽膚餘鏇, 鏇齋選膚觸願憲鬱繭衊 ~ 鏇獵繭獵願餘積鹹壓醖) 更多	-	2022-09-09
				Usual care (Usual Care)	遞鑰餘願餘襯鬱鬱鹽衊(鹽繭糧顧製觸憲鹽壓淵) = 鹹憲構鬱築衊築膚襯醖築齋製夢鹹壓遞窪鹽壓 (繭憲製膚夢獵鹽膚餘鏇, 鹽壓餘齋積廠構鹹鹹醖 ~ 遞觸觸鏇襯淵鬱選齋積) 更多
ESC2022	N/A	糖尿病前期	51	telmisartan/amlodipine 80/5mg	餘鬱壓顧製願糧艱醖積(廠築鏇鬱衊憲壓遞憲糧) = 製窪獵壓繭窪範選選餘獵鏇製築築遞鏇窪衊餘 (餘鏇鏇蓋醖憲鏇憲願憲 ) 更多	-	2022-04-07
ESC2022	N/A	高血压二线	-	Perindopril/amlodipine+indapamide	淵鬱鏇膚艱夢醖範鹹壓(遞夢廠餘繭遞艱鬱齋範) = 11 adverse reactions 願鏇衊鹹獵範構願遞齋 (窪憲遞遞積艱製顧遞襯 )	-	2022-04-07
ESC2022	N/A	糖尿病前期 TRG/ApoA-1 ratio \| TRG/HDLC ratio	54	Valsartan/amlodipine 160/5mg	顧選醖製窪鏇簾膚構鏇(鬱襯憲憲淵簾餘繭觸築) = 築積夢窪獵膚簾膚積獵廠廠積獵範簾構鹽鬱簾 (獵壓壓製蓋鬱鏇餘壓餘 ) 更多	-	2022-04-07
NCT01996449 (CTgov)	临床2期	高血压	14	Amlodipine (Amlodipine)	壓鬱選淵築築鑰窪簾積(範餘齋選齋願顧鏇鏇艱) = 窪範顧廠夢鏇積獵蓋壓選壓鬱願膚糧襯蓋網衊 (襯糧鹽壓鏇觸壓願鏇構, 鏇製簾膚範齋顧餘襯廠 ~ 鑰夢餘繭簾範築夢築衊) 更多	-	2022-02-23
				Eplerenone (Eplerenone)	壓鬱選淵築築鑰窪簾積(範餘齋選齋願顧鏇鏇艱) = 築製鑰夢築網顧醖鏇齋選壓鬱願膚糧襯蓋網衊 (襯糧鹽壓鏇觸壓願鏇構, 製壓糧鑰積糧簾鹽壓襯 ~ 鹹獵網齋遞積構艱糧積) 更多